Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells $815,107.84 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 27,098 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $30.08, for a total transaction of $815,107.84. Following the completion of the sale, the chief executive officer now owns 27,918 shares in the company, valued at $839,773.44. This represents a 49.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.00, for a total value of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total value of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.38, for a total transaction of $1,118,663.94.
• On Tuesday, November 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $30.89 on Monday. The business has a 50-day simple moving average of $28.22 and a 200 day simple moving average of $22.19. The firm has a market capitalization of $6.75 billion, a price-to-earnings ratio of 70.20 and a beta of 1.31. Hims & Hers Health, Inc. has a one year low of $8.51 and a one year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period in the prior year, the firm earned ($0.04) earnings per share. Hims & Hers Health’s revenue for the quarter was up 77.1% on a year-over-year basis. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Raleigh Capital Management Inc. raised its holdings in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after purchasing an additional 2,152 shares during the last quarter. Quest Partners LLC lifted its holdings in shares of Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares in the last quarter. CWM LLC boosted its position in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Hims & Hers Health by 115.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock valued at $110,000 after buying an additional 2,442 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. TD Cowen reissued a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. BTIG Research initiated coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Piper Sandler raised their price objective on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Monday, January 6th. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their target price for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, Morgan Stanley initiated coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price target for the company. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.